| Description | SCO-267 is a potent allosteric full agonist of the GPR40 receptor, making it a valuable tool in studying chronic diseases like diabetes. |
| In vitro | SCO-267 (CHO cells) activates the Gα q , Gα s , and Gα 12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand[1]. |
| In vivo | SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1]. Animal Model: N-STZ rats[1]Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect. |
| molecular weight | 614.787 |
| Molecular formula | C36H46N4O5 |
| CAS | 1656261-09-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293. |